drugset
drugset / Trial / NCT03732495

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

NCT03732495 ↗

Phase 2 Unknown 35 enrolled Centre Leon Berard
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the combination of lenvatinib with denosumab in bone-predominant metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas. All patients will receive this combination of treatments.

Timeline

Start
2019-07-26
Primary completion
2022-12-15
Completion
2023-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 24 mg —
Background Denosumab Monoclonal antibody 120 mg —

Indications

differentiated thyroid carcinoma